The next C.R. Bard transvaginal mesh trial is scheduled for Dec. 3 in the U.S. District Court in West Virginia, according to court documents. The Rottenstein Law Group LLP, which represents clients in transvaginal mesh injury lawsuits, reports on updates related to Bard mesh trials, in addition to offering a brief rundown of the multimillion dollar vaginal mesh verdicts to date.
Read more: Transvaginal Mesh Injury Lawsuits: Next C.R. Bard Trial Slated for Dec. 3, Rottenstein Law Group LLP Reports
Johnson & Johnson and its subsidiary DePuy Orthopaedics agreed Nov. 19 to a DePuy ASR hip settlement of at least $2.5 billion, according to news reports. The Rottenstein Law Group LLP, a metal-on-metal hip implant law firm, notes that those who underwent revision surgery will be eligible for a settlement, but settlement is not required.
Read more via PrWeb: DePuy ASR Lawsuit Settlement News: Johnson & Johnson Agrees to Settle for at Least $2.5 Billion, Notes Rottenstein Law Group LLP
There are six federal case consolidations in U.S. District Court for the Southern District of West Virginia for as many major mesh manufacturers, and bellwether trials have been scheduled for most of them, according to court documents. The Rottenstein Law Group LLP, which represents clients in vaginal mesh lawsuits, notes that the next trial scheduled, which involves C.R. Bard, is coming up on Dec. 3.
Read more: Vaginal Mesh Lawsuits News: Federal Bellwether Trials Scheduled, Rottenstein Law Group LLP Reports
Johnson & Johnson subsidiary DePuy Orthopaedics will reportedly offer $4 billion in DePuy settlements to resolve thousands of DePuy ASR hip lawsuits in state and federal courts, according to a Nov. 12 Bloomberg Businessweek article.* The Rottenstein Law Group LLP notes that part of the agreement says that future patients who find their hip implants are allegedly defective will still be able to sue, meaning that the value of the settlement could increase.
Read more at PrWeb: DePuy ASR Settlement Update: Rottenstein Law Group LLP Comments on $4 Billion DePuy Hip Settlement News
According to reports from the U.S. Food & Drug Administration (FDA), GranuFlo and NaturaLyte may contribute to increased bicarbonate levels in patients with kidney problems. As a result, patients may experience hemodialysis metabolic alkalosis, a significant risk factor for various health complications, namely, arrhythmia, confusion, death, hemodialysis cardiac arrest, hemodialysis cardiopulmonary arrest, low blood pressure, stroke, and sudden cardiac arrest. In fact, affected patients are pursuing GranuFlo and NaturaLyte lawsuit against the products’ manufacturer, Fresenius Medical Care.